Clinical trial · Interventional
Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer
A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced or Recurrent Endometrial Cancer | Endometrial Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin | Drug | Cisplatin | ALIAS |
| Doctaxel | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Chemotherapy
- description
- Docetaxel 70mg/m2BSA + Cisplatin 60mg/m2BSA, q 3 weeks, 8cycles
- interventionNames
- Drug: Doctaxel
- Drug: Cisplatin
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 3 months after completion of study treatment
Secondary outcomes (3)
- measure
- Progression-free survival
- timeFrame
- 2 years after completion of study treatment
- measure
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed chemotherapy naïve endometrial cancer * One of following histology Endometrioid, UPSC, CCCa, squamous, adenosquamous, mixed * FIGO stage IVb or recurrent endometrial cancer (incurable by surgery and/or RT) * At least one measurable lesion by RECIST on CT * ECOG PS: 0-2 * Age: 20-75 * Adequate organ function BM: ANC≥1,000/mm3, Plt≥100X103/mm3 Kidney: Creatinine\<1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT\< 3×UNL, T- bil\<1.5 mg/ mm3 * Informed Consent * Contraception during study period Exclusion Criteria: * Previous chemotherapy * RT, hormone therapy, or immunotherapy within 1 month * Other malignant disease * Uncontrolled medical disease * Infection requiring antibiotics * Symptomatic CHF, RF, Angina, Arrhythmia, etc. * Neurosis or psychosis * Pregnancy, breast-feeding * Etc.
References
Publications (0)
Data not yet available